Stock analysts at Oppenheimer assumed coverage on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research note issued on Thursday, The Fly reports. The brokerage set an “outperform” rating on the stock.
Several other equities analysts have also recently issued reports on the company. Lake Street Capital lifted their price objective on DiaMedica Therapeutics from $14.00 to $28.00 and gave the stock a “buy” rating in a report on Monday, January 4th. Craig Hallum lifted their price target on DiaMedica Therapeutics from $15.00 to $20.00 in a research note on Monday, March 15th. Finally, Roth Capital assumed coverage on shares of DiaMedica Therapeutics in a research report on Wednesday, February 17th. They issued a “buy” rating and a $38.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, DiaMedica Therapeutics has an average rating of “Buy” and a consensus target price of $20.46.
Shares of DMAC stock traded down $0.01 during mid-day trading on Thursday, hitting $9.34. The stock had a trading volume of 676 shares, compared to its average volume of 145,259. DiaMedica Therapeutics has a fifty-two week low of $2.88 and a fifty-two week high of $10.88. The firm has a market cap of $175.37 million, a PE ratio of -12.32 and a beta of 2.58. The company’s 50-day simple moving average is $9.53 and its 200-day simple moving average is $7.31.
Several large investors have recently bought and sold shares of the stock. Virtu Financial LLC acquired a new stake in DiaMedica Therapeutics in the 4th quarter valued at $159,000. Jane Street Group LLC acquired a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at about $127,000. ExodusPoint Capital Management LP purchased a new stake in shares of DiaMedica Therapeutics during the 4th quarter valued at about $133,000. Northern Trust Corp lifted its position in DiaMedica Therapeutics by 3.6% during the 4th quarter. Northern Trust Corp now owns 120,989 shares of the company’s stock worth $1,227,000 after acquiring an additional 4,222 shares in the last quarter. Finally, Valeo Financial Advisors LLC purchased a new position in DiaMedica Therapeutics in the 4th quarter worth approximately $51,000. Institutional investors and hedge funds own 35.77% of the company’s stock.
DiaMedica Therapeutics Company Profile
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke.
Further Reading: What are catch-up contributions?
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.